Boryung Pharmaceutical and IMBDX Sign Agreement to Develop Therapeutics Using Liquid Biopsy

[Asia Economy Reporter Cho Hyun-ui] Boryung Pharmaceutical announced on the 7th that it has signed a technology utilization and therapeutic development agreement with liquid biopsy company IMBDX for tumor diagnosis.

Boryung Pharmaceutical plans to develop personalized therapeutics using the liquid biopsy technology owned by IMBDX. When conducting clinical trials for anticancer drugs, they will apply liquid biopsy technology to develop companion diagnostic technologies and also conduct joint research to analyze drug resistance biomarkers and discover new therapeutic targets for mutations.

Liquid biopsy technology analyzes genetic information through circulating tumor cells (CTCs) or circulating tumor DNA present in bodily fluids such as blood, cerebrospinal fluid, and urine to diagnose various diseases including cancer. IMBDX possesses technology to detect ultra-low levels of circulating tumor DNA shed from cancer cells in the blood to diagnose cancer.

Ahn Jae-hyun, CEO of Boryung Pharmaceutical, stated, "As we are currently strengthening our capabilities in the anticancer sector as a mid- to long-term growth engine, this agreement will serve as an opportunity to establish a system that connects diagnosis to therapeutics."

This content was produced with the assistance of AI translation services.